GENERAL
Aurobindo Pharma Acquires A1 Biochem Research Unit For ₹147 Cr
Aurobindo Pharma Ltd, through its wholly owned subsidiary Apitoria Pharma Pvt Ltd, has acquired the contract research services business of A1 Biochem Group for ₹147 crore, strengthening its presence across the active pharmaceutical ingredient (API) lifecycle. As part of the transaction, Apitoria now holds an 80% stake in A1 Biochem Labs (India) Pvt Ltd, while […]
CW Bureau
·
Oct 2, 2026
GENERAL
Morepen Labs Files First ANDA, Eyes US Market With Sitagliptin Tablets
Morepen Laboratories Ltd has submitted its first Abbreviated New Drug Application (ANDA) to the US Food and Drug Administration (FDA) for Sitagliptin tablets USP in 25 mg, 50 mg and 100 mg strengths, marking the company’s entry into integrated finished dosage development and US regulatory filings. The submission expands Morepen’s established active pharmaceutical ingredient (API) […]
CW Bureau
·
Sep 28, 2026
STARTUP/TECHNOLOGY
RPG LS Transfers API Business To Its Arm, InvAscent To Invest ₹243 Cr
RPG Life Sciences Ltd (RPG LS) has executed a Business Transfer Agreement to transfer its Active Pharmaceutical Ingredients (API) business to its wholly owned subsidiary, RPG Active Pharma Ltd, on a slump sale basis as a going concern. The restructuring is part of the company’s strategy to create a focused API business with dedicated capital, […]
CW Bureau
·
Jul 30, 2026
GENERAL
Aurobindo Pharma To Acquire 80% Stake In A1 Biochem CRO Business
Aurobindo Pharma Ltd, through its wholly owned subsidiary Apitoria Pharma Pvt Ltd, will acquire an 80% stake in the Contract Research Services business of A1 Biochem Group. The acquisition will be completed within 90 to 120 days for cash consideration at an enterprise value of $17 million on a debt-free and cash-free basis. Building CRDMO […]
CW Bureau
·
Jul 24, 2026
MANUFACTURING
Tube Investments, N Govindarajan To Invest ₹100 Cr In 3xper Innoventure
Murugappa group firm Tube Investments of India Ltd (TII) has entered into a supplementary agreement with 3xper Innoventure Ltd and N Govindarajan to invest ₹75 crore by TII and ₹25 crore by Govindarajan respectively, in compulsorily convertible preference shares (CCPS) of the company. TII subsidiary 3xper operates in the contract development and manufacturing organisation (CDMO) […]
CW Bureau
·
Apr 23, 2026
